{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "37d5e247",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "db0ae21c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Token request code: 200\n",
      "Token acquired successfully.\n",
      "\n",
      "1. =============== TRY LPR API ===============\n",
      "ERROR with status: 401\n",
      "Text Content: \n",
      "\n",
      "2. =============== TRY LPR METADATA API ===============\n",
      "ERROR with status: 404\n",
      "Text Content: \n",
      "\n",
      "3.=============== TRY CLINICAL TRIALS API ===============\n",
      "Clinical Trials request successfully\n",
      "JSON Content: {'study': {'pk_study': 116445, 'study_number': '0000-100191-P01', 'Publish_State': 'Publish', 'public_modified_data': None, 'Current_Study_Status': 'Approved', 'sitecore_start_date': '2022-02-02T00:00:00', 'unpub_start_date': None, 'nct_number': 'NCT03115333', 'irb_protocol_id': '17-006593', 'Sponsor_Protocol_ID': 'EAF151', 'Study_Metadata_Json': None, 'Metadata_Added_Date': '2020-01-29T19:38:35', 'Metadata_Last_Modified_Date': None, 'Eligibility_Criteria': '<p><strong>Inclusion Criteria:</strong></p>  <ul>  <li>Histologically proven intracranial glioblastoma or gliosarcoma at initial surgery  <ul>   <li>Patients will be eligible if the original histology was low-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made (high-grade transformation)</li>  </ul>  </li>  <li>Karnofsky performance status &gt;= 70</li>  <li>Women must not be pregnant or breast-feeding</li>  <li>Progression of disease assessed by local site using Revised Assessment in Neuro-Oncology (RANO) criteria, with plan to give whole-dose bevacizumab therapeutically, either as single therapy or in conjunction with other chemotherapeutic regimens; patients getting bevacizumab to support additional radiation therapy or immunotherapy, or primarily for reduction of edema rather than for tumor treatment, are excluded; this must be the patient?s initial recurrence</li>  <li>Patient must not have been treated previously with immunotherapies (vaccines, checkpoint inhibitors, T-cells)</li>  <li>Intratumoral hemorrhage (acute, subacute, or chronic) as seen on hemosiderin-sensitive (gradient-echo) MRI may preclude patient inclusion because of anticipated limited evaluation due to magnetic susceptibility artifact on the heavily T2-weighted DSC-MRI images; if the region of enhancing tumor not affected by blooming artifact on the hemosiderin-sensitive images does not meet the 10 x 10 x 10 mm ?measurable enhancement? threshold specified elsewhere, the patient is ineligible</li>  <li>Progressive enhancement (&gt; 25% increase in contrast enhancing volume compared to nadir) on MRI within 14 days of registration, &gt;= 42 days since completion of radiation/temozolomide therapy, and &gt;= 28 days since surgical resection or cytotoxic chemotherapy; measurable enhancement is defined as two perpendicular in-plane diameters of at least 10 mm and at least 10 mm in the 3rd orthogonal direction</li>  <li>Patients must be able to tolerate brain MRI scans with dynamic intravenous gadolinium-based contrast agent injections  <ul>   <li>Ability to withstand 22 gauge intravenous (IV) placement</li>   <li>No history of untreatable claustrophobia</li>   <li>No magnetic resonance (MR) incompatible implants/devices or metallic foreign bodies</li>   <li>No contraindication to intravenous contrast administration   <ul>    <li>Adequate organ function, including adequate renal function defined as estimated glomerular filtration rate (eGFR) &gt;= 40 mL/min/1.73 m^2 as calculated per institution standard of care, and meeting local site requirements for intravenous administration of gadolinium-based MRI contrast agents</li>   </ul>   </li>   <li>No known allergy-like reaction to gadolinium or moderate or severe allergic reactions to one or more allergens as defined by the American College of Radiology (ACR); patient may be eligible if willing to undergo pre-treatment as defined by the institution&#39;s policy and/or ACR guidance</li>   <li>Weight compatible with limits imposed by the MRI scanner table</li>  </ul>  </li>  <li>Patient must be scheduled to receive treatment with a standard dose regimen of bevacizumab (bevacizumab infusion on days 1 and 15 of a 28-day treatment cycle); patient can be treated with bevacizumab alone or in combination with other chemotherapies</li> </ul>', 'ec_last_modified_date': None, 'Site_Summary_JSON': [{'Site_Abbreviation': 'RST', 'Site_Contact_Display_Name': 'Keith Severson', 'Site_Contact_Email': 'Severson.Keith@mayo.edu', 'Site_Contact_Phone_Number': '(507) 284-4073', 'Site_Full_Name': 'Rochester', 'Site_PI': 'Timothy Kaufmann', 'Site_PI_LANID': 'TJK09', 'Site_PI_PERID': '12788023', 'Status_Mapped': 'Open for Enrollment', 'Status_Raw': 'Accruing'}, {'Site_Abbreviation': 'FLA', 'Site_Contact_Display_Name': 'Cancer Center Clinical Trials Referral Office', 'Site_Contact_Email': None, 'Site_Contact_Phone_Number': '(855) 776-0015', 'Site_Full_Name': 'Florida', 'Site_PI': 'Amit Desai', 'Site_PI_LANID': None, 'Site_PI_PERID': '21119520', 'Status_Mapped': 'Open for Enrollment', 'Status_Raw': 'Accruing'}, {'Site_Abbreviation': 'ARZ', 'Site_Contact_Display_Name': 'Cancer Center Clinical Trials Referral Office', 'Site_Contact_Email': None, 'Site_Contact_Phone_Number': '(855) 776-0015', 'Site_Full_Name': 'Arizona', 'Site_PI': 'Leland Hu', 'Site_PI_LANID': 'M060167', 'Site_PI_PERID': '13803611', 'Status_Mapped': 'Open for Enrollment', 'Status_Raw': 'Accruing'}], 'record_modified_date': None, 'Status_Modified_Date': None, 'PI_Modified_Date': '2020-01-30T22:19:08', 'Contact_Modified_Date': '2022-02-02T13:13:45', 'Latest_Modified_Date': '2022-02-02T13:13:45', 'POC_ID': '', 'Row_Loaded_Date': '2025-04-09T18:23:19.358670'}}\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "import os\n",
    "import json\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "key = os.getenv('APIGEE_X_KEY')\n",
    "secret = os.getenv('APIGEE_X_SECRET')\n",
    "\n",
    "def generate_token(key, secret):    \n",
    "    # print(key)\n",
    "    # print(secret)\n",
    "    url = \"https://dev.mcc.apix.mayo.edu/oauth/token\"\n",
    "    payload = f'grant_type=client_credentials&client_id={key}&client_secret={secret}'\n",
    "    headers = {\n",
    "      'Content-Type': 'application/x-www-form-urlencoded'\n",
    "    }\n",
    "    \n",
    "    response = requests.request(\"POST\", url, headers=headers, data=payload)    \n",
    "    print(\"Token request code:\", response.status_code)\n",
    "    if response.status_code == 200:\n",
    "        print(\"Token acquired successfully.\")\n",
    "    return response.json()['access_token']\n",
    "\n",
    "token = generate_token(key, secret)\n",
    "\n",
    "# Try LPR API\n",
    "print(\"\\n1. =============== TRY LPR API ===============\")\n",
    "response = requests.get(\n",
    "    'https://dev.mcc.apix.mayo.edu/v3/mcc/fhir/r4/Patient?family:exact=Smith',\n",
    "    headers = { 'Authorization': f'Bearer {token}' }\n",
    ")\n",
    "\n",
    "if response.status_code == 200:\n",
    "    print(\"LPR request successfully\")\n",
    "    json_content = response.json()\n",
    "    print(f\"JSON Content: {json_content}\")\n",
    "else:\n",
    "    # If not JSON, access as plain text\n",
    "    print(\"ERROR with status:\", response.status_code)\n",
    "    text_content = response.text\n",
    "    print(f\"Text Content: {text_content}\")\n",
    "\n",
    "\n",
    "# Try LPR Metadata API\n",
    "print(\"\\n2. =============== TRY LPR METADATA API ===============\")\n",
    "response = requests.get(\n",
    "    'https://dev.mcc.apix.mayo.edu/dna-lpr-fhir-metadata-internal',\n",
    "    headers = { 'Authorization': f'Bearer {token}' }\n",
    ")\n",
    "\n",
    "if response.status_code == 200:\n",
    "    print(\"LPR request successfully\")\n",
    "    json_content = response.json()\n",
    "    print(f\"JSON Content: {json_content}\")\n",
    "else:\n",
    "    # If not JSON, access as plain text\n",
    "    print(\"ERROR with status:\", response.status_code)\n",
    "    text_content = response.text\n",
    "    print(f\"Text Content: {text_content}\")\n",
    "\n",
    "\n",
    "# Try Clinical Trials API\n",
    "print(\"\\n3.=============== TRY CLINICAL TRIALS API ===============\")\n",
    "response = requests.get(\n",
    "    'https://dev.mcc.apix.mayo.edu/dps-clinstudies/v1/first',\n",
    "    headers = { 'Authorization': f'Bearer {token}' }\n",
    ")\n",
    "\n",
    "if response.status_code == 200:\n",
    "    print(\"Clinical Trials request successfully\")\n",
    "    json_content = response.json()\n",
    "    print(f\"JSON Content: {json_content}\")\n",
    "else:\n",
    "    # If not JSON, access as plain text\n",
    "    print(\"ERROR with status:\", response.status_code)\n",
    "    text_content = response.text\n",
    "    print(f\"Text Content: {text_content}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "74c3ea73",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "apigeex",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
